These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25069467)

  • 1. Neuroendocrine cancer: CLARINET: new option for NETS.
    Hutchinson L
    Nat Rev Endocrinol; 2014 Oct; 10(10):577. PubMed ID: 25069467
    [No Abstract]   [Full Text] [Related]  

  • 2. Lanreotide slows growth of neuroendocrine cancer.
    Cancer Discov; 2014 Oct; 4(10):OF3. PubMed ID: 25274694
    [No Abstract]   [Full Text] [Related]  

  • 3. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Yang F; Jin C; Fu D
    N Engl J Med; 2014 Oct; 371(16):1556. PubMed ID: 25317883
    [No Abstract]   [Full Text] [Related]  

  • 4. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ruszniewski P
    N Engl J Med; 2014 Oct; 371(16):1556-7. PubMed ID: 25317881
    [No Abstract]   [Full Text] [Related]  

  • 5. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Ozdemir N; Yazici O; Zengin N
    N Engl J Med; 2014 Oct; 371(16):1555-6. PubMed ID: 25317882
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine cancer: CLARINET: new option for NETs.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073004
    [No Abstract]   [Full Text] [Related]  

  • 9. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
    Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
    Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
    [No Abstract]   [Full Text] [Related]  

  • 14. Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors?
    Völter V; Peschel C
    J Clin Oncol; 2004 Feb; 22(3):573; author reply 574-5. PubMed ID: 14752089
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Caplin ME
    Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
    Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
    Khagi S; Saif MW
    JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
    Hansen CP; Knigge U
    Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.